The introduction of the drug in Australia is sparking significant excitement within the healthcare community. This innovative dual agonist – affecting both GLP-1 and GIP targets – presents a seemingly powerful approach for individuals trying meaningful weight loss. Preliminary trial findings sugg… Read More